BR112018014908A2 - vacina de opioide sintético - Google Patents
vacina de opioide sintéticoInfo
- Publication number
- BR112018014908A2 BR112018014908A2 BR112018014908-0A BR112018014908A BR112018014908A2 BR 112018014908 A2 BR112018014908 A2 BR 112018014908A2 BR 112018014908 A BR112018014908 A BR 112018014908A BR 112018014908 A2 BR112018014908 A2 BR 112018014908A2
- Authority
- BR
- Brazil
- Prior art keywords
- fentanyl
- vaccine
- drug
- analogs
- synthetic
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title abstract 2
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 abstract 7
- 229940079593 drug Drugs 0.000 abstract 4
- 239000003814 drug Substances 0.000 abstract 4
- 229960002428 fentanyl Drugs 0.000 abstract 4
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 abstract 2
- 108010060123 Conjugate Vaccines Proteins 0.000 abstract 1
- 206010013654 Drug abuse Diseases 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 abstract 1
- 208000026251 Opioid-Related disease Diseases 0.000 abstract 1
- 238000004458 analytical method Methods 0.000 abstract 1
- 229940031670 conjugate vaccine Drugs 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000000383 hazardous chemical Substances 0.000 abstract 1
- 238000009169 immunotherapy Methods 0.000 abstract 1
- 231100000518 lethal Toxicity 0.000 abstract 1
- 230000001665 lethal effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 229960005181 morphine Drugs 0.000 abstract 1
- 201000000988 opioid abuse Diseases 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 238000012216 screening Methods 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 abstract 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 abstract 1
- 231100000027 toxicology Toxicity 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0013—Therapeutic immunisation against small organic molecules, e.g. cocaine, nicotine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Neurology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662281262P | 2016-01-21 | 2016-01-21 | |
| US62/281,262 | 2016-01-21 | ||
| PCT/US2017/013865 WO2017127390A1 (en) | 2016-01-21 | 2017-01-18 | Synthetic opioid vaccine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112018014908A2 true BR112018014908A2 (pt) | 2018-12-18 |
Family
ID=59362842
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112018014908-0A BR112018014908A2 (pt) | 2016-01-21 | 2017-01-18 | vacina de opioide sintético |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11305010B2 (enExample) |
| EP (1) | EP3405475B1 (enExample) |
| JP (1) | JP2019506390A (enExample) |
| CN (1) | CN108884127A (enExample) |
| BR (1) | BR112018014908A2 (enExample) |
| RU (1) | RU2018130106A (enExample) |
| WO (1) | WO2017127390A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11660331B2 (en) | 2017-11-09 | 2023-05-30 | The Scripps Research Institute | Heroin vaccine |
| WO2020006563A1 (en) * | 2018-06-29 | 2020-01-02 | Marquette University | Fluorinated compounds as ph-sensitive analgesics |
| WO2021092446A1 (en) * | 2019-11-08 | 2021-05-14 | Regents Of The University Of Minnesota | Fentanyl hapten, fentanyl hapten-conjugates, and methods for making and using |
| US20230100186A1 (en) * | 2020-01-13 | 2023-03-30 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Fentanyl haptens for the preparation of a fentanyl vaccine |
| US20230126276A1 (en) * | 2020-03-13 | 2023-04-27 | Regents Of The University Of Minnesota | Fentanyl haptens, fentanyl hapten conjugates, and methods for making and using |
| US20240307517A1 (en) * | 2021-05-10 | 2024-09-19 | Cornell University | Development of a highly efficient second generation fentanyl-conjugate vaccine to treat fentanyl addiction |
| WO2024215826A2 (en) * | 2023-04-13 | 2024-10-17 | Avicenna Biotech Research, Llc | Compositions and methods for treating fentanyl dependence |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5283066A (en) * | 1992-02-19 | 1994-02-01 | Development Center For Biotechnology | Method of stimulating an immune response by using a hapten |
| CA2132342A1 (en) | 1992-04-06 | 1993-10-14 | Kenneth F. Buechler | Novel opiate derivatives and protein and polypeptide opiate derivative conjugates and labels |
| US6262265B1 (en) | 1999-06-18 | 2001-07-17 | Microgenics Corporation | Non-hydrolyzable analogs of heroin metabolites suitable for use in immunoassay |
| CN100402084C (zh) | 2001-11-16 | 2008-07-16 | 兰多克斯实验室有限公司 | 检测或定量芬太尼或其类似物的代谢物的方法和试剂盒 |
| IN2008CN05409A (enExample) * | 2002-07-18 | 2015-10-02 | Cytos Biotechnology Ag | |
| WO2004111202A2 (en) * | 2003-03-07 | 2004-12-23 | Incyte Corporation | Neurotransmission-association proteins |
| MXPA04006617A (es) | 2004-07-07 | 2006-01-12 | Inst Nac De Psiquiatria Ramon | Proceso para la preparacion y uso de una vacuna bivalente contra la adiccion a la morfina-heroina. |
| MX2007009545A (es) * | 2005-02-08 | 2008-03-11 | Genzyme Corp | Anticuerpos para tgfbeta. |
| US20110182918A1 (en) * | 2008-06-13 | 2011-07-28 | Nabi Biopharmaceuticals | Personalized drug treatment and smoking cessation kit and method |
| WO2010120121A2 (ko) * | 2009-04-15 | 2010-10-21 | 포항공과대학교 산학협력단 | 표적 특이적 비항체 단백질 및 이의 제조 방법 |
| PH12013500990A1 (en) * | 2010-11-19 | 2022-11-23 | Eisai R&D Man Co Ltd | Neutralizing anti-ccl20 antibodies |
| CA2857645A1 (en) * | 2011-11-30 | 2013-06-06 | Wellstat Diagnostics, Llc | Assays, antibodies, immunogens and compositions related to 5-fu |
| WO2013095321A1 (en) | 2011-12-21 | 2013-06-27 | The Scripps Research Institute | Heroin haptens, immunoconjugates and related uses |
| US20140093525A1 (en) * | 2012-09-17 | 2014-04-03 | Minneapolis Medical Research Foundation | Compositions and methods of treating opioid addiction |
| US9981043B2 (en) | 2013-02-08 | 2018-05-29 | Regents Of The University Of Minnesota | Analgesic conjugates |
| US9213029B2 (en) * | 2013-06-25 | 2015-12-15 | Samsung Electronics Co., Ltd. | Method for diagnosing breast cancer by detection of polymeric immunoglobulin receptor in vesicles isolated from patients |
-
2017
- 2017-01-18 BR BR112018014908-0A patent/BR112018014908A2/pt not_active Application Discontinuation
- 2017-01-18 EP EP17741829.0A patent/EP3405475B1/en active Active
- 2017-01-18 RU RU2018130106A patent/RU2018130106A/ru unknown
- 2017-01-18 WO PCT/US2017/013865 patent/WO2017127390A1/en not_active Ceased
- 2017-01-18 CN CN201780007832.8A patent/CN108884127A/zh active Pending
- 2017-01-18 US US16/071,199 patent/US11305010B2/en active Active
- 2017-01-18 JP JP2018537799A patent/JP2019506390A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN108884127A (zh) | 2018-11-23 |
| RU2018130106A3 (enExample) | 2020-05-26 |
| US11305010B2 (en) | 2022-04-19 |
| EP3405475A4 (en) | 2019-08-28 |
| CA3015336A1 (en) | 2017-07-27 |
| JP2019506390A (ja) | 2019-03-07 |
| RU2018130106A (ru) | 2020-02-21 |
| US20210128720A1 (en) | 2021-05-06 |
| EP3405475A1 (en) | 2018-11-28 |
| WO2017127390A1 (en) | 2017-07-27 |
| EP3405475B1 (en) | 2022-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112018014908A2 (pt) | vacina de opioide sintético | |
| BR112017011005A2 (pt) | novos indazóis substituídos, métodos para sua produção, preparações farmacêuticas que contêm os novos indazóis substituídos e o uso dos indazóis substituídos para produzir os medicamentos. | |
| CY1124787T1 (el) | Αντισωματα anti-gitr και μεθοδοι χρησης αυτων | |
| CY1124791T1 (el) | Μορια δεσμευσης ειδικα για cd73 και χρησεις αυτων | |
| Kim et al. | Supplementation of influenza split vaccines with conserved M2 ectodomains overcomes strain specificity and provides long-term cross protection | |
| MX2019013023A (es) | Proteina de fusion con receptor tgf-?, y uso farmaceutico de la misma. | |
| PH12019502576A1 (en) | Bis-octahydrophenanthrene carboxamides and protein conjugates thereof | |
| EP4279135A3 (en) | Use of a vegf antagonist to treat diabetic retinopathy | |
| Rudenko et al. | H7N3 live attenuated influenza vaccine has a potential to protect against new H7N9 avian influenza virus | |
| MX394875B (es) | Terapia combinada para trastornos neuropsiquiatricos sensibles al antagonista de nmdar. | |
| MX2017009047A (es) | Regimen de dosificacion para antagonistas de madcam. | |
| MA50488B1 (fr) | Procédé de préparation d'une formulation de poudre sèche contenant un anticholinergique, un corticostéroïde et un bêta-adrénergique | |
| CL2017001859A1 (es) | Inhalador de polvo seco que comprende propionato de fluticasona y xinafosfato de salmeterol | |
| Mohapatra et al. | In silico screening of phytochemicals of Ocimum sanctum against main protease of SARS-CoV-2 | |
| Bronte | Tumors STING adaptive antitumor immunity | |
| Seidel et al. | A novel category of antigens enabling CTL immunity to tumor escape variants: Cinderella antigens | |
| Sambol et al. | Rethinking dosing regimen selection of piperaquine for malaria chemoprevention: a simulation study | |
| AR029336A1 (es) | Peptidos utiles para preparar medicamentos para el tratamiento, prevencion o mejoramiento de estados alergicos, inmunogenos,epitopos y mimotopos, vacunas, ligandos, composiciones farmaceuticas; uso de los peptidos ,de los ligandos en la preparacion de medicamentos; proceso para preparar vacunas y pr | |
| Mori et al. | Underlying mechanisms of methamphetamine-induced self-injurious behavior and lethal effects in mice | |
| Ganguly et al. | Biomedicine and biotechnology: Public health impact | |
| MX2023004718A (es) | Antigeno quimerico que comprende el dominio extracelular de pd-l1. | |
| Martoni et al. | Comparative crossover trial of two intravenous doses of granisetron (1 mg vs 3 mg)+ dexamethasone in the prevention of acute cis-platinum-induced emesis. | |
| MA53272A (fr) | Procédé de préparation d'une formulation pharmaceutique d'anticorps | |
| MX2022005245A (es) | Regimen de dosificacion de anticuerpos anti-cd27 para el tratamiento de cancer. | |
| EA202090333A1 (ru) | Фармацевтические комбинации, содержащие антитело к bst1 и аналог цитидина |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |